Bicycle Therapeutics picks up former Pfizer head as new SVP of Pre-Clinical Development
The Cambridge based biotechnology firm Bicycle therapeutics, has announced former Pfizer head Dr Phil Jeffrey as the company’s new Senior Vice President of Pre-Clinical Development.
Dr Jeffrey, formerly Head of Translational Sciences at Pfizer’s Rare Disease Research Unit, brings 35 years of experience in preclinical, clinical and translational drug discovery to the role, having overseen the development of more than 25 different compounds throughout his career.
“Phil brings a wealth of experience in drug discovery and development,” said Dr Kevin Lee, Chief Executive Officer of Bicycle Therapeutics. “He has wide expertise in drug discovery from lead optimisation through to the clinic, across multiple disease areas and modalities. We are delighted to welcome him to the team and believe his deep knowledge will be a huge asset as we continue to grow our pipeline to develop first-in-class treatments for cancers and other diseases with high unmet medical needs.”
Having gained a PhD in pharmacokinetics and drug metabolism from the University of Sheffield in 1991, Dr Jeffrey is an honorary professor at Queen Mary University of London and a member of the editorial board for the British Journal of Pharmacology and Xenobiotica. The experienced pharmaceutical industry professional has also authored more than 60 peer reviewed papers and four chapters in books.
Having previously worked for The Upjohn Company and SmithKlineBeecham, Dr Jeffrey joined British firm GSK as Head: Medicinal Chemistry and DMPK, Immunepigenetics DPU in 2009, taking on a more senior role as Head Translational Discovery the following year.
Dr Jeffrey later worked for Pfizer in London, Cambridge, Massachusetts and Cambridge, UK joining as head of translational sciences in 2014. Dr Jeffrey left the British multinational in 2017.
Dr Jeffrey commented: “Bicycle is creating an entirely new therapeutic class of highly targeted, uniquely versatile medicines with strong potential to address the clinical needs of patients with a range of serious diseases. It’s rare to have the opportunity to be involved with such a novel technology, and I am very excited to be able to help the team shape and expand the portfolio and contribute to Bicycle’s efforts to make life-changing impacts on patients.”